Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

January 23, 2024

Study Completion Date

September 30, 2025

Conditions
Prostate CancerProstate AdenocarcinomaProstate Neoplasm
Interventions
DIAGNOSTIC_TEST

PET Scan

PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.

DRUG

[18F]PSMA-1007 Injection

\[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.

DIAGNOSTIC_TEST

Sodium MRI

Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.

DIAGNOSTIC_TEST

Multiparametric MRI

MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
collaborator

Western University, Canada

OTHER

collaborator

United States Department of Defense

FED

collaborator

Centre for Probe Development and Commercialization

OTHER

lead

Glenn Bauman

OTHER